Base de dados : MEDLINE
Pesquisa : E05.927.852 [Categoria DeCS]
Referências encontradas : 275 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 28 ir para página                         

  1 / 275 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27774794
[Au] Autor:Seay JS; Mandigo M; Kish J; Menard J; Marsh S; Kobetz E
[Ad] Endereço:a Miller School of Medicine , University of Miami , Miami , FL , USA.
[Ti] Título:Intravaginal practices are associated with greater odds of high-risk HPV infection in Haitian women.
[So] Source:Ethn Health;22(3):257-265, 2017 Jun.
[Is] ISSN:1465-3419
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: Haitian women have the highest incidence of cervical cancer within the Western hemisphere. Intravaginal hygiene practices have been linked with human papilloma virus (HPV) infection and cervical dysplasia. These practices, known as 'twalet deba' in Haitian Creole, are common among Haitian women and are performed with various natural and synthetic agents. As part of a community-based participatory research initiative aimed at reducing cervical cancer disparities in rural Haiti, we explored the use of intravaginal agents and their associations with high-risk HPV infection. DESIGN: Community Health Workers recruited 416 women for cervical self-sampling from two neighborhoods within Thomonde, Haiti. Participants were interviewed regarding intravaginal hygiene practices and completed a cervical self-sampling procedure. Cervical samples were analyzed for the presence of high-risk HPV infection. Associations between each intravaginal agent and high-risk HPV infection were examined via univariate logistic regression analyses, as well as via multivariate analyses controlling for sociodemographic factors and concurrent agent use. RESULTS: Nearly all women (97.1%) performed twalet deba, using a variety of herbal and commercially produced intravaginal agents. Approximately 11% of the participants tested positive for high-risk HPV. Pigeon pea and lime juice were the only agents found to be associated with high-risk HPV in the univariate analyses, with women who used these agents being approximately twice as likely to have high-risk HPV as those who did not. Only pigeon pea remained significantly associated with high-risk HPV after controlling for sociodemographic factors and concurrent agent use. CONCLUSION: Two agents, pigeon pea and lime juice, may contribute to risk for HPV infection in this population. Results suggest that in addition to cervical cancer screening interventions, future preventive initiatives should focus on minimizing risk by advocating for the use of less-toxic twalet deba alternatives.
[Mh] Termos MeSH primário: Conhecimentos, Atitudes e Prática em Saúde/etnologia
Higiene
Infecções por Papillomavirus/etnologia
Ducha Vaginal/efeitos adversos
[Mh] Termos MeSH secundário: Administração Intravaginal
Adulto
Compostos de Alúmen/administração & dosagem
Cajanus
Citrus aurantiifolia
Pesquisa Participativa Baseada na Comunidade
Feminino
Sucos de Frutas e Vegetais
Haiti/epidemiologia
Seres Humanos
Infecções por Papillomavirus/epidemiologia
Infecções por Papillomavirus/virologia
Preparações de Plantas/administração & dosagem
Permanganato de Potássio/administração & dosagem
Fatores de Risco
Sabões/administração & dosagem
Ducha Vaginal/métodos
Saúde da Mulher/etnologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Alum Compounds); 0 (Plant Preparations); 0 (Soaps); 00OT1QX5U4 (Potassium Permanganate); 34S289N54E (aluminum sulfate)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180301
[Lr] Data última revisão:
180301
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161025
[St] Status:MEDLINE
[do] DOI:10.1080/13557858.2016.1246423


  2 / 275 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28520912
[Au] Autor:Jordan SJ; Olson KM; Barnes S; Wilson LS; Berryhill TF; Bakshi R; Brown LT; Press CG; Geisler WM
[Ad] Endereço:Department of Medicine.
[Ti] Título:Lower Levels of Cervicovaginal Tryptophan Are Associated With Natural Clearance of Chlamydia in Women.
[So] Source:J Infect Dis;215(12):1888-1892, 2017 Jun 15.
[Is] ISSN:1537-6613
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Chlamydiatrachomatis (Ct) infection causes significant morbidity. In vitro studies demonstrate that Ct growth inhibition occurs by interferon-gamma (IFN-γ)-mediated depletion of intracellular tryptophan, and some Ct strains utilize extracellular indole to restore tryptophan levels. Whether tryptophan levels are associated with Ct infection clearance in humans remains unknown. We evaluated tryptophan, indole, and IFN-γ levels in cervicovaginal lavages from women with either naturally cleared or persisting Ct infection. Women who cleared infection had significantly lower tryptophan levels and trended toward lower IFN-γ levels compared to women with persisting infection. Due to its volatility, indole was not measurable in either group.
[Mh] Termos MeSH primário: Infecções por Chlamydia/tratamento farmacológico
Chlamydia trachomatis/imunologia
Interferon gama/análise
Triptofano/análise
[Mh] Termos MeSH secundário: Adolescente
Adulto
Azitromicina/administração & dosagem
Feminino
Seres Humanos
Meia-Idade
Ducha Vaginal
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
82115-62-6 (Interferon-gamma); 83905-01-5 (Azithromycin); 8DUH1N11BX (Tryptophan)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170907
[Lr] Data última revisão:
170907
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170519
[St] Status:MEDLINE
[do] DOI:10.1093/infdis/jix240


  3 / 275 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28494795
[Au] Autor:Alcaide ML; Chisembele M; Malupande E; Rodriguez VJ; Fischl MA; Arheart K; Jones DL
[Ad] Endereço:Department of Medicine, Division of Infectious Diseases, University of Miami Miller School of Medicine, 1120 NW 14 Street, CRB 864 (D-90A), Miami, Fl, 33136, USA. malcaide@med.miami.edu.
[Ti] Título:A bio-behavioral intervention to decrease intravaginal practices and bacterial vaginosis among HIV infected Zambian women, a randomized pilot study.
[So] Source:BMC Infect Dis;17(1):338, 2017 May 12.
[Is] ISSN:1471-2334
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Intravaginal practices (IVP) (cleansing or introducing products inside the vagina for hygiene, health or to please sexual partners) are common among women with HIV. IVP increase the risk of developing bacterial Vaginosis (BV), the most common genital infection associated with transmission of sexually transmitted infections and HIV. This study tested a pilot intervention to reduce IVP and BV in HIV infected women in Zambia. METHODS: One hundred twenty-eight HIV infected women engaging in IVP were randomized to two conditions: enhanced standard of care (n = 70) and experimental (n = 58) from May 1, 2013 to February 28, 2014. All participants received a brief educational counseling session on discontinuation of IVP, and those with BV, were provided with medical treatment for BV. Women in the experimental condition received an additional group-based, culturally tailored intervention. Participants completed questionnaires assessing sexual risk factors and IVP and were assessed for BV using Nugent criteria at baseline, 6 months and 12 months. RESULTS: At 12-month, the proportion of self-reported use of IVPs decreased in the experimental condition: soap (28% vs. 47%); cloth or a rag (19% vs. 38%); and traditional medicines (22% vs. 42%) (all p < 0.05)) compared with the enhanced standard of care condition. The prevalence of BV at 6 and 12 months did not differ by study condition but averaging over study condition, prevalence of BV decreased from 64.2% at baseline to 15.6% at 6 months (p < 0.01) and to 23.6% at 12 months (p = 0.15). Using an enhanced standard of care approach and an enhanced standard of care + a group intervention, IVP and BV decreased over time, but the experimental condition had greater reduction in self-reported use of IVP. CONCLUSIONS: Future studies should address interventions in communities with high burden of IVP, BV and HIV. Interventions that could be administered during routine medical care and decrease IVP and BV are needed, and should be considered part of women's health programs. TRIAL REGISTRATION NUMBER: NCT03134924 (retrospectively registered 21st April 2017).
[Mh] Termos MeSH primário: Infecções por HIV/complicações
Vaginose Bacteriana/prevenção & controle
[Mh] Termos MeSH secundário: Adulto
Terapia Comportamental
Feminino
Infecções por HIV/psicologia
Seres Humanos
Higiene
Projetos Piloto
Fatores de Risco
Comportamento Sexual
Parceiros Sexuais
Inquéritos e Questionários
Vagina/microbiologia
Ducha Vaginal/efeitos adversos
Ducha Vaginal/psicologia
Vaginose Bacteriana/etiologia
Vaginose Bacteriana/psicologia
Saúde da Mulher
Adulto Jovem
Zâmbia
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170814
[Lr] Data última revisão:
170814
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170513
[St] Status:MEDLINE
[do] DOI:10.1186/s12879-017-2436-3


  4 / 275 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28073073
[Au] Autor:Barreiros L; Cunha-Reis C; Silva EM; Carvalho JR; das Neves J; Sarmento B; Segundo MA
[Ad] Endereço:UCIBIO, REQUIMTE, Departamento de Ciências Químicas, Faculdade de Farmácia, Universidade do Porto, Rua de Jorge Viterbo Ferreira 228, 4050-313 Porto, Portugal. Electronic address: lbarreiros@ff.up.pt.
[Ti] Título:Development and validation of a liquid chromatography-MS/MS method for simultaneous quantification of tenofovir and efavirenz in biological tissues and fluids.
[So] Source:J Pharm Biomed Anal;136:120-125, 2017 Mar 20.
[Is] ISSN:1873-264X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Millions of people worldwide live with human immunodeficiency virus (HIV) infection thus justifying the continuous search for new prevention and treatment strategies, including topical microbicide products combining antiretroviral drugs (ARVs) such as tenofovir (TFV) and efavirenz (EFV). Therefore, the aim of this work was to develop and validate a high performance liquid chromatography method coupled to triple quadrupole-tandem mass spectrometry (HPLC-MS/MS) for the quantification of TFV and EFV in biological matrices (mouse vaginal tissue, vaginal lavage and blood plasma). Chromatographic separation was achieved using a reversed phase C18 column (3µm, 100×2.1mm) at 45°C and elution in gradient mode using a combination of 0.1% (v/v) formic acid in water and 0.1% (v/v) formic acid in acetonitrile at 0.35mLmin . Total run time was 9min, with retention time of 2.8 and 4.1min for TFV and EFV, respectively. The MS was operated in positive ionization mode (ESI+) for TFV and in negative ionization mode (ESI-) for EFV detection. Data were acquired in selected reaction monitoring (SRM) mode and deuterated ARVs were employed as internal standards. Calibration curves were linear for ARV concentrations ranging from 4 to 500ngmL with LOD and LOQ for both analytes ≤0.4 and ≤0.7ngmL in sample extracts, respectively. The method was found to be specific, accurate (96.0-106.0% of nominal values) and precise (RSD<2.4%) in all matrices. Both TFV and EFV were found to be stable in all matrices after standing 24h at room temperature (20°C) or in the autosampler, and after three freeze-thawing cycles. Mean recovery values of ARVs spiked in mice tissues or fluids were ≥88.4%. Matrix effects were observed for EFV determination in tissue and plasma extracts but compensated by the use of deuterated internal standards. The proposed methodology was successfully applied to a pharmacokinetic study following intravaginal administration of both ARVs.
[Mh] Termos MeSH primário: Fármacos Anti-HIV/análise
Benzoxazinas/análise
Cromatografia Líquida de Alta Pressão/métodos
Espectrometria de Massas em Tandem/métodos
Tenofovir/análise
[Mh] Termos MeSH secundário: Administração Intravaginal
Animais
Fármacos Anti-HIV/administração & dosagem
Fármacos Anti-HIV/sangue
Benzoxazinas/administração & dosagem
Benzoxazinas/sangue
Combinação de Medicamentos
Feminino
Limite de Detecção
Camundongos
Reprodutibilidade dos Testes
Tenofovir/administração & dosagem
Tenofovir/sangue
Vagina/química
Ducha Vaginal
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-HIV Agents); 0 (Benzoxazines); 0 (Drug Combinations); 99YXE507IL (Tenofovir); JE6H2O27P8 (efavirenz)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170619
[Lr] Data última revisão:
170619
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170111
[St] Status:MEDLINE


  5 / 275 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:27553042
[Au] Autor:Bui TC; Thai TN; Tran LT; Shete SS; Ramondetta LM; Basen-Engquist KM
[Ad] Endereço:Department of Behavioral Science.
[Ti] Título:Association Between Vaginal Douching and Genital Human Papillomavirus Infection Among Women in the United States.
[So] Source:J Infect Dis;214(9):1370-1375, 2016 Nov 01.
[Is] ISSN:1537-6613
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The very few studies that have examined the association between vaginal douching and genital human papillomavirus (HPV) infection have found contrary results. We investigated the associations between douching and numbers of HPV genotypes infecting 1271 participants aged 20-49 years in the 2003-2004 US National Health and Nutrition Examination Survey. After controlling for relevant covariates, douching in the past 6 months was significantly associated with infection by higher numbers of all genital HPV types (relative risk ratio, 1.26; 95% confidence interval, 1.03-1.54) and HPV high-risk types (1.40; 1.09-1.80).
[Mh] Termos MeSH primário: Papillomaviridae/isolamento & purificação
Infecções por Papillomavirus/etiologia
Ducha Vaginal/efeitos adversos
[Mh] Termos MeSH secundário: Adulto
Feminino
Genótipo
Seres Humanos
Meia-Idade
Inquéritos Nutricionais
Papillomaviridae/genética
Infecções por Papillomavirus/virologia
Estados Unidos
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170605
[Lr] Data última revisão:
170605
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:160825
[St] Status:MEDLINE


  6 / 275 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27544812
[Au] Autor:Machado A; Cunha-Reis C; Araújo F; Nunes R; Seabra V; Ferreira D; das Neves J; Sarmento B
[Ad] Endereço:i3S - Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal; INEB - Instituto de Engenharia Biomédica, Universidade do Porto, Porto, Portugal.
[Ti] Título:Development and in vivo safety assessment of tenofovir-loaded nanoparticles-in-film as a novel vaginal microbicide delivery system.
[So] Source:Acta Biomater;44:332-40, 2016 10 15.
[Is] ISSN:1878-7568
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:UNLABELLED: Topical pre-exposure prophylaxis (PrEP) with antiretroviral drugs holds promise in preventing vaginal transmission of HIV. However, significant biomedical and social issues found in multiple past clinical trials still need to be addressed in order to optimize protection and users' adherence. One approach may be the development of improved microbicide products. A novel delivery platform comprising drug-loaded nanoparticles (NPs) incorporated into a thin polymeric film base (NPs-in-film) was developed in order to allow the vaginal administration of the microbicide drug candidate tenofovir. The system was optimized for relevant physicochemical features and characterized for biological properties, namely cytotoxicity and safety in a mouse model. Tenofovir-loaded poly(lactic-co-glycolic acid) (PLGA)/stearylamine (SA) composite NPs with mean diameter of 127nm were obtained with drug association efficiency above 50%, and further incorporated into an approximately 115µm thick, hydroxypropyl methylcellulose/poly(vinyl alcohol)-based film. The system was shown to possess suitable mechanical properties for vaginal administration and to quickly disintegrate in approximately 9min upon contact with a simulated vaginal fluid (SVF). The original osmolarity and pH of SVF was not affected by the film. Tenofovir was also released in a biphasic fashion (around 30% of the drug in 15min, followed by sustained release up to 24h). The incorporation of NPs further improved the adhesive potential of the film to ex vivo pig vaginal mucosa. Cytotoxicity of NPs and film was significantly increased by the incorporation of SA, but remained at levels considered tolerable for vaginal delivery of tenofovir. Moreover, histological analysis of genital tissues and cytokine/chemokine levels in vaginal lavages upon 14days of daily vaginal administration to mice confirmed that tenofovir-loaded NPs-in-film was safe and did not induce any apparent histological changes or pro-inflammatory response. Overall, obtained data support that the proposed delivery system combining the use of polymeric NPs and a film base may constitute an exciting alternative for the vaginal administration of microbicide drugs in the context of topical PrEP. STATEMENT OF SIGNIFICANCE: The development of nanotechnology-based microbicides is a recent but promising research field seeking for new strategies to circumvent HIV sexual transmission. Different reports detail on the multiple potential advantages of using drug nanocarriers for such purpose. However, one important issue being frequently neglected regards the development of vehicles for the administration of microbicide nanosystems. In this study, we propose and detail on the development of a nanoparticle-in-film system for the vaginal delivery of the microbicide drug candidate tenofovir. This is an innovative approach that, to our best knowledge, had never been tested for tenofovir. Results, including those from in vivo testing, sustain that the proposed system is safe and holds potential for further development as a vaginal microbicide product.
[Mh] Termos MeSH primário: Anti-Infecciosos/farmacologia
Sistemas de Liberação de Medicamentos
Nanopartículas/química
Tenofovir/farmacologia
[Mh] Termos MeSH secundário: Administração Intravaginal
Animais
Linhagem Celular
Quimiocinas/metabolismo
Liberação Controlada de Fármacos
Feminino
Seres Humanos
Ácido Láctico/química
Camundongos
Nanopartículas/ultraestrutura
Ácido Poliglicólico/química
Espectrometria por Raios X
Sus scrofa
Fatores de Tempo
Ducha Vaginal
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Anti-Infective Agents); 0 (Chemokines); 0 (polylactic acid-polyglycolic acid copolymer); 26009-03-0 (Polyglycolic Acid); 33X04XA5AT (Lactic Acid); 99YXE507IL (Tenofovir)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171120
[Lr] Data última revisão:
171120
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160822
[St] Status:MEDLINE


  7 / 275 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27393267
[Au] Autor:Hughes BL; Dutt R; Raker C; Barthelemy M; Rossoll RM; Ramratnam B; Wira CR; Cu-Uvin S
[Ad] Endereço:Department of Obstetrics and Gynecology, Division of Maternal Fetal Medicine, Warren Alpert Medical School of Brown University, Women and Infants Hospital, Providence, RI. Electronic address: bhughes@wihri.org.
[Ti] Título:The impact of pregnancy on anti-HIV activity of cervicovaginal secretions.
[So] Source:Am J Obstet Gynecol;215(6):748.e1-748.e12, 2016 Dec.
[Is] ISSN:1097-6868
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Mucosal immunity of the female genital tract plays a critical role in defense against sexually transmitted infections like HIV. Pregnancy is associated with both structural and immunologic alterations in the genital mucosa, but the impact of these changes on its ability to suppress HIV infection is unknown. Current epidemiologic data are conflicting as to whether pregnancy increases the risk of HIV acquisition. OBJECTIVE: The purpose of this study was to define the association between antimicrobial peptides and chemokines in cervicovaginal secretions and in vitro HIV infectivity among pregnant and nonpregnant women. STUDY DESIGN: Forty pregnant and 37 nonpregnant women were enrolled in a prospective longitudinal cohort study at a single tertiary care women's hospital in Providence, RI. Cervicovaginal lavage was performed at each study visit. For pregnant women, study visits occurred once per trimester, and there was an optional postpartum visit. For nonpregnant women, study visits occurred across a single cycle that was timed to occur in the proliferative, ovulatory, and secretory phases based on the presumption of a regular menstrual cycle. The impact of cervicovaginal lavage on HIV infectivity was evaluated using a TZM-bl assay and compared between pregnant and nonpregnant women for each visit. The previously validated TZM-bl assay, which uses a luciferase reporting gene to indicate HIV infection of TZM-bl cells, was measured with a luminometer with higher relative light units that indicate greater levels of in vitro HIV infection. Immune mediators were measured with a multiplex bead assay. HIV infectivity and median concentration of each mediator were compared between pregnant and nonpregnant groups with the Wilcoxon rank sum test. RESULTS: Cervicovaginal fluid from pregnant and nonpregnant women significantly decreased HIV infectivity in both groups compared with positive control (virus only; P<.01), but infectivity was not different between groups (P≥.44). During the second and third trimesters, pregnant women experienced suppression of several cervicovaginal immune mediators that included human beta defensin-2; lactoferrin; macrophage inflammatory protein-3α; regulated on activation, normally T-cell expressed and secreted; and stromal cell-derived factor-1 (all P≤.05). The antimicrobial peptide elafin was significantly correlated with HIV infectivity in both groups across all visits, except at the postpartum visit in the pregnant group (n=16). Secretory leukocyte protease inhibitor also was correlated significantly with infectivity across all visits, but in nonpregnant women only (P≤.03). CONCLUSION: Cervicovaginal secretions from both pregnant and nonpregnant women contain immune mediators that are associated with HIV infectivity in an in vitro assay; however, infectivity was not different between pregnant and nonpregnant groups. If pregnant women are at increased risk for HIV infection, it is unlikely to be mediated by alterations in the effectiveness of these protective secretions.
[Mh] Termos MeSH primário: Colo do Útero/imunologia
Infecções por HIV/imunologia
HIV-1/imunologia
Imunidade nas Mucosas/imunologia
Gravidez/imunologia
Vagina/imunologia
[Mh] Termos MeSH secundário: Adulto
Estudos de Casos e Controles
Colo do Útero/secreção
Quimiocina CCL20/imunologia
Quimiocina CXCL12/imunologia
Elafina/imunologia
Feminino
Seres Humanos
Lactoferrina/imunologia
Estudos Longitudinais
Estudos Prospectivos
Inibidor Secretado de Peptidases Leucocitárias
Vagina/secreção
Ducha Vaginal
Adulto Jovem
beta-Defensinas/imunologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Chemokine CCL20); 0 (Chemokine CXCL12); 0 (Elafin); 0 (Secretory Leukocyte Peptidase Inhibitor); 0 (beta-Defensins); EC 3.4.21.- (Lactoferrin)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:170531
[Lr] Data última revisão:
170531
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:160710
[St] Status:MEDLINE


  8 / 275 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
Texto completo
[PMID]:27215916
[Au] Autor:Attieh E; Maalouf S; Roumieh D; Abdayem P; AbiTayeh G; Kesrouani A
[Ad] Endereço:Obstetrics and Gynecology Department, Faculty of Medicine, Saint Joseph University, Hotel-Dieu de France Hospital, PO Box: 166830, Adib Ishac Street, Achrafie, Beirut, Lebanon.
[Ti] Título:Feminine hygiene practices among female patients and nurses in Lebanon.
[So] Source:Reprod Health;13(1):59, 2016 May 23.
[Is] ISSN:1742-4755
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Inappropriate feminine hygiene practices are related to vulvovaginitis. We investigated the prevalence of personal hygiene habits among Lebanese women as well as their awareness of adequate practices. METHODS: Consists of a cross-sectional observational study. Female patients and nurses at Hotel-Dieu de France University Hospital in Beirut- Lebanon filled a questionnaire about their intimate hygiene habits and knowledge of proper practices. RESULTS: The study included 249 women. 21.3 % of the 136 nurses and 38.9 % of the 113 patients reported a history of vulvovaginitis. The majority of women took an intimate bath at least twice daily. 14 % of nurses and 17 % of patients douched.20. Seven percent of the nurses and 43.4 % of the patients used wet wipes. 1.5 % of nurses and 4.4 % of patients used feminine deodorant sprays. There was a significant lack of awareness mainly among patients about suitable hygiene practices as well for their adverse effects. CONCLUSION: Education provided by nurses, and other healthcare providers is essential to promote reproductive health among Lebanese women.
[Mh] Termos MeSH primário: Conhecimentos, Atitudes e Prática em Saúde
Higiene
Enfermeiras e Enfermeiros
Pacientes
[Mh] Termos MeSH secundário: Adulto
Estudos Transversais
Feminino
Seres Humanos
Líbano
Saúde Reprodutiva
Ducha Vaginal/efeitos adversos
Ducha Vaginal/utilização
Vulvovaginite/etiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; OBSERVATIONAL STUDY
[Em] Mês de entrada:1703
[Cu] Atualização por classe:170924
[Lr] Data última revisão:
170924
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160525
[St] Status:MEDLINE
[do] DOI:10.1186/s12978-016-0182-4


  9 / 275 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:27122262
[Au] Autor:Yanikkerem E; Yasayan A
[Ad] Endereço:Celal Bayar University, School of Health, Istasyonmevki, Uncubozkoykampusu, Manisa, Turkey.
[Ti] Título:Vaginal douching practice: Frequency, associated factors and relationship with vulvovaginal symptoms.
[So] Source:J Pak Med Assoc;66(4):387-92, 2016 Apr.
[Is] ISSN:0030-9982
[Cp] País de publicação:Pakistan
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: To determine the frequency, associated factors and relationship with vulvovaginal symptoms and vaginal douching among Turkish women. METHODS: The cross-sectional, analytical study was conducted at Merkez Efendi Hospital, Manisa, Turkey, from January to June 2014 using a questionnaire. Statistical analysis was carried out using SPSS 17. RESULTS: Of the total 343 women in the study, 91(26.5%) had reported vaginal douching in the preceding year. Statistically significant relationship was determined between the vaginal douching behaviour and couples who had low educationand low income levels, having unplanned pregnancy and had someone in their neighbourhood who douched (p< 0.05 each). The most common reason for using vaginal douching was reported to be cleanliness by 85(93.4%) women, prevention of genital infections 75(82.4%), cleaning after/before sexual intercourse 72(79%), during menstruation 49(54%), prevention of vaginal discharge 69(76%), decreasing of unpleasant odours 65(71.4%) and religious beliefs 46(50.5%). Self-reported history of vaginal infection was significantly more common for women who douched compared those who did not (p< 0.05). CONCLUSIONS: Healthcare providers should determine the reason and risky groups of women and educate the women to stop the vaginal douching behaviour and harmful effects of vaginal douching.
[Mh] Termos MeSH primário: Conhecimentos, Atitudes e Prática em Saúde
Ducha Vaginal/utilização
[Mh] Termos MeSH secundário: Adulto
Candidíase Vulvovaginal/epidemiologia
Estudos Transversais
Dispareunia/epidemiologia
Escolaridade
Feminino
Seres Humanos
Higiene
Renda/estatística & dados numéricos
Dor Pélvica/epidemiologia
Religião
Inquéritos e Questionários
Turquia/epidemiologia
Descarga Vaginal/epidemiologia
Vulvovaginite/epidemiologia
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1701
[Cu] Atualização por classe:170113
[Lr] Data última revisão:
170113
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160429
[St] Status:MEDLINE


  10 / 275 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27026477
[Au] Autor:Jais M; Younes N; Chapman S; Cu-Uvin S; Ghosh M
[Ad] Endereço:Department of Epidemiology and Biostatistics, The George Washington University, Washington, DC.
[Ti] Título:Reduced levels of genital tract immune biomarkers in postmenopausal women: implications for HIV acquisition.
[So] Source:Am J Obstet Gynecol;215(3):324.e1-324.e10, 2016 Sep.
[Is] ISSN:1097-6868
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Rates of HIV infections are increasing in older adults. Although it is known that the HIV/AIDS epidemics affects women disproportionately, little is known regarding immune functions in the genital tract of postmenopausal women, as relevant to HIV susceptibility. OBJECTIVE: The objective of the study was to compare levels of female reproductive tract immune mediators that are important for HIV-associated immune responses as well as intrinsic anti-HIV activity in the cervical vaginal lavages collected from HIV-negative pre- and postmenopausal women. STUDY DESIGN: Cervical vaginal lavage from 20 premenopausal and 20 postmenopausal women were assayed for interleukin-6, interleukin-8, tumor necrosis factor-α, secretory leukocyte protease inhibitor, elafin, human ß-defensin-2, and macrophage inflammatory protein-3α using standard enzyme-linked immunosorbent assays. Anti-HIV activity of cervical-vaginal lavage was measured using TZM-bl indicator cells against HIV-1 IIIB and BaL. Whereas each postmenopausal woman provided only 1 sample, each premenopausal woman provided 3 samples, during proliferative, ovulatory, and secretory stages, based on menstrual dates. RESULTS: We observed significantly lower levels of tumor necrosis factor-α, MIP-3α, secretory leukocyte protease inhibitor, elafin, and human ß-defensin-2 in cervical vaginal lavage from postmenopausal women compared with premenopausal women. Inhibition of HIV-1 infection was observed for both pre- and postmenopausal women, but cervical vaginal lavage from postmenopausal women showed significantly higher inhibition against HIV-1 BaL after adjusting for total protein concentration, genital pH, and reproductive tract infections. No change in mediators or HIV inhibition was observed through the stages of menstrual cycle. In addition, we observed that postmenopausal women with reproductive tract infections had significantly higher levels of tumor necrosis factor-α and significantly lower levels of interleukin-8, which were not observed in premenopausal women. CONCLUSION: Our findings suggest that female reproductive tract immune microenvironment is distinct in HIV-negative postmenopausal women. Further studies are needed to assess the risk of HIV acquisition/transmission in this population.
[Mh] Termos MeSH primário: Infecções por HIV/transmissão
Infecções do Sistema Genital/transmissão
Vagina/química
[Mh] Termos MeSH secundário: Adulto
Biomarcadores/análise
Quimiocina CCL20/análise
Elafina/análise
Feminino
Infecções por HIV/imunologia
Seres Humanos
Interleucina-6/análise
Interleucina-8/análise
Meia-Idade
Pós-Menopausa
Infecções do Sistema Genital/imunologia
Inibidor Secretado de Peptidases Leucocitárias/análise
Fator de Necrose Tumoral alfa/análise
Ducha Vaginal
beta-Defensinas/análise
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Biomarkers); 0 (CCL20 protein, human); 0 (Chemokine CCL20); 0 (DEFB4A protein, human); 0 (Elafin); 0 (Interleukin-6); 0 (Interleukin-8); 0 (Secretory Leukocyte Peptidase Inhibitor); 0 (Tumor Necrosis Factor-alpha); 0 (beta-Defensins)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:170518
[Lr] Data última revisão:
170518
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:160331
[St] Status:MEDLINE



página 1 de 28 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde